ID   EPHA3_HUMAN             Reviewed;         983 AA.
AC   P29320; Q9H2V3; Q9H2V4;
DT   01-DEC-1992, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 2.
DT   12-OCT-2022, entry version 224.
DE   RecName: Full=Ephrin type-A receptor 3;
DE            EC=2.7.10.1;
DE   AltName: Full=EPH-like kinase 4;
DE            Short=EK4;
DE            Short=hEK4;
DE   AltName: Full=HEK;
DE            Short=Human embryo kinase;
DE   AltName: Full=Tyrosine-protein kinase TYRO4;
DE   AltName: Full=Tyrosine-protein kinase receptor ETK1;
DE            Short=Eph-like tyrosine kinase 1;
DE   Flags: Precursor;
GN   Name=EPHA3; Synonyms=ETK, ETK1, HEK, TYRO4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ARG-924.
RX   PubMed=1311845; DOI=10.1073/pnas.89.5.1611;
RA   Wicks I.P., Wilkinson D., Salvaris E., Boyd A.W.;
RT   "Molecular cloning of HEK, the gene encoding a receptor tyrosine kinase
RT   expressed by human lymphoid tumor cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:1611-1615(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Melanoma;
RX   PubMed=10987298;
RA   Chiari R., Hames G., Stroobant V., Texier C., Maillere B., Boon T.,
RA   Coulie P.G.;
RT   "Identification of a tumor-specific shared antigen derived from an Eph
RT   receptor and presented to CD4 T cells on HLA class II molecules.";
RL   Cancer Res. 60:4855-4863(2000).
RN   [3]
RP   PROTEIN SEQUENCE OF 21-29 AND 840-860, AND CHARACTERIZATION.
RX   PubMed=1737782; DOI=10.1016/s0021-9258(19)50725-6;
RA   Boyd A.W., Ward L.D., Wicks I.P., Simpson R.J., Salvaris E., Wilks A.,
RA   Welch K., Loudovaris M., Rockman S., Busmanis I.;
RT   "Isolation and characterization of a novel receptor-type protein tyrosine
RT   kinase (hek) from a human pre-B cell line.";
RL   J. Biol. Chem. 267:3262-3267(1992).
RN   [4]
RP   NOMENCLATURE.
RX   PubMed=9267020; DOI=10.1016/s0092-8674(00)80500-0;
RG   Eph nomenclature committee;
RT   "Unified nomenclature for Eph family receptors and their ligands, the
RT   ephrins.";
RL   Cell 90:403-404(1997).
RN   [5]
RP   FUNCTION IN CELL-CELL ADHESION, EFNA5-BINDING, SUBCELLULAR LOCATION
RP   (ISOFORM 1), INTERACTION WITH CRK, AND PHOSPHORYLATION AT TYR-596; TYR-602
RP   AND TYR-779.
RX   PubMed=11870224; DOI=10.1242/jcs.115.5.1059;
RA   Lawrenson I.D., Wimmer-Kleikamp S.H., Lock P., Schoenwaelder S.M., Down M.,
RA   Boyd A.W., Alewood P.F., Lackmann M.;
RT   "Ephrin-A5 induces rounding, blebbing and de-adhesion of EphA3-expressing
RT   293T and melanoma cells by CrkII and Rho-mediated signalling.";
RL   J. Cell Sci. 115:1059-1072(2002).
RN   [6]
RP   INVOLVEMENT IN CRC.
RX   PubMed=12738854; DOI=10.1126/science.1082596;
RA   Bardelli A., Parsons D.W., Silliman N., Ptak J., Szabo S., Saha S.,
RA   Markowitz S., Willson J.K., Parmigiani G., Kinzler K.W., Vogelstein B.,
RA   Velculescu V.E.;
RT   "Mutational analysis of the tyrosine kinome in colorectal cancers.";
RL   Science 300:949-949(2003).
RN   [7]
RP   EPHRIN LIGAND-BINDING, OLIGOMERIZATION, MUTAGENESIS OF VAL-133 AND PHE-152,
RP   AND INTERACTION WITH CRK.
RX   PubMed=14660665; DOI=10.1074/jbc.m309326200;
RA   Smith F.M., Vearing C., Lackmann M., Treutlein H., Himanen J., Chen K.,
RA   Saul A., Nikolov D., Boyd A.W.;
RT   "Dissecting the EphA3/Ephrin-A5 interactions using a novel functional
RT   mutagenesis screen.";
RL   J. Biol. Chem. 279:9522-9531(2004).
RN   [8]
RP   IDENTIFICATION IN A COMPLEX WITH ADAM10 AND EFNA5.
RX   PubMed=16239146; DOI=10.1016/j.cell.2005.08.014;
RA   Janes P.W., Saha N., Barton W.A., Kolev M.V., Wimmer-Kleikamp S.H.,
RA   Nievergall E., Blobel C.P., Himanen J.P., Lackmann M., Nikolov D.B.;
RT   "Adam meets Eph: an ADAM substrate recognition module acts as a molecular
RT   switch for ephrin cleavage in trans.";
RL   Cell 123:291-304(2005).
RN   [9]
RP   EFNA5 LIGAND-BINDING.
RX   PubMed=15901737; DOI=10.1074/jbc.m504972200;
RA   Day B., To C., Himanen J.P., Smith F.M., Nikolov D.B., Boyd A.W.,
RA   Lackmann M.;
RT   "Three distinct molecular surfaces in ephrin-A5 are essential for a
RT   functional interaction with EphA3.";
RL   J. Biol. Chem. 280:26526-26532(2005).
RN   [10]
RP   INTERACTION WITH PTPN1, PHOSPHORYLATION, DEPHOSPHORYLATION BY PTPN1, AND
RP   SUBCELLULAR LOCATION (ISOFORM 2).
RX   PubMed=21135139; DOI=10.1083/jcb.201005035;
RA   Nievergall E., Janes P.W., Stegmayer C., Vail M.E., Haj F.G., Teng S.W.,
RA   Neel B.G., Bastiaens P.I., Lackmann M.;
RT   "PTP1B regulates Eph receptor function and trafficking.";
RL   J. Cell Biol. 191:1189-1203(2010).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (1.07 ANGSTROMS) OF 577-947 IN COMPLEX WITH ATP
RP   ANALOG, IDENTIFICATION BY MASS SPECTROMETRY, PHOSPHORYLATION AT TYR-596;
RP   TYR-602 AND TYR-701, AND MUTAGENESIS OF TYR-596; TYR-602; TYR-742 AND
RP   SER-768.
RX   PubMed=18547520; DOI=10.1016/j.str.2008.03.008;
RA   Davis T.L., Walker J.R., Loppnau P., Butler-Cole C., Allali-Hassani A.,
RA   Dhe-Paganon S.;
RT   "Autoregulation by the juxtamembrane region of the human ephrin receptor
RT   tyrosine kinase A3 (EphA3).";
RL   Structure 16:873-884(2008).
RN   [12]
RP   VARIANTS [LARGE SCALE ANALYSIS] LYS-37; SER-85; LEU-621 AND ASN-806.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [13]
RP   VARIANTS LYS-660 AND MET-933.
RX   PubMed=16941478; DOI=10.1002/humu.9452;
RA   Wood L.D., Calhoun E.S., Silliman N., Ptak J., Szabo S., Powell S.M.,
RA   Riggins G.J., Wang T.L., Yan H., Gazdar A., Kern S.E., Pennacchio L.,
RA   Kinzler K.W., Vogelstein B., Velculescu V.E.;
RT   "Somatic mutations of GUCY2F, EPHA3, and NTRK3 in human cancers.";
RL   Hum. Mutat. 27:1060-1061(2006).
RN   [14]
RP   VARIANTS [LARGE SCALE ANALYSIS] TYR-229; PHE-449; LEU-518; VAL-564;
RP   SER-568; PRO-590; GLU-766; GLY-777; HIS-914 AND ARG-924.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [15]
RP   VARIANT ASN-207.
RX   PubMed=20838624; DOI=10.1371/journal.pone.0012653;
RA   Corbo V., Ritelli R., Barbi S., Funel N., Campani D., Bardelli A.,
RA   Scarpa A.;
RT   "Mutational profiling of kinases in human tumours of pancreatic origin
RT   identifies candidate cancer genes in ductal and ampulla of vater
RT   carcinomas.";
RL   PLoS ONE 5:E12653-E12653(2010).
CC   -!- FUNCTION: Receptor tyrosine kinase which binds promiscuously membrane-
CC       bound ephrin family ligands residing on adjacent cells, leading to
CC       contact-dependent bidirectional signaling into neighboring cells. The
CC       signaling pathway downstream of the receptor is referred to as forward
CC       signaling while the signaling pathway downstream of the ephrin ligand
CC       is referred to as reverse signaling. Highly promiscuous for ephrin-A
CC       ligands it binds preferentially EFNA5. Upon activation by EFNA5
CC       regulates cell-cell adhesion, cytoskeletal organization and cell
CC       migration. Plays a role in cardiac cells migration and differentiation
CC       and regulates the formation of the atrioventricular canal and septum
CC       during development probably through activation by EFNA1. Involved in
CC       the retinotectal mapping of neurons. May also control the segregation
CC       but not the guidance of motor and sensory axons during neuromuscular
CC       circuit development. {ECO:0000269|PubMed:11870224}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.1;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028};
CC   -!- SUBUNIT: Heterotetramer upon binding of the ligand. The heterotetramer
CC       is composed of an ephrin dimer and a receptor dimer. Oligomerization is
CC       probably required to induce biological responses. Forms a ternary
CC       EFNA5-EPHA3-ADAM10 complex mediating EFNA5 extracellular domain
CC       shedding by ADAM10 which regulates the EFNA5-EPHA3 complex
CC       internalization and function. Interacts with NCK1 (via SH2 domain);
CC       mediates EFNA5-EPHA3 signaling (By similarity). Interacts
CC       (phosphorylated) with PTPN1; dephosphorylates EPHA3 and may regulate
CC       its trafficking and function. Interacts (phosphorylated) with CRK;
CC       mediates EFNA5-EPHA3 signaling through RHOA GTPase activation.
CC       {ECO:0000250, ECO:0000269|PubMed:11870224, ECO:0000269|PubMed:14660665,
CC       ECO:0000269|PubMed:16239146, ECO:0000269|PubMed:18547520,
CC       ECO:0000269|PubMed:21135139}.
CC   -!- INTERACTION:
CC       P29320; P29317: EPHA2; NbExp=3; IntAct=EBI-1641575, EBI-702104;
CC       P29320; Q15375: EPHA7; NbExp=2; IntAct=EBI-1641575, EBI-1383428;
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Cell membrane
CC       {ECO:0000269|PubMed:11870224}; Single-pass type I membrane protein
CC       {ECO:0000255}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 2]: Secreted
CC       {ECO:0000269|PubMed:21135139}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P29320-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P29320-2; Sequence=VSP_002995, VSP_002996;
CC   -!- TISSUE SPECIFICITY: Widely expressed. Highest level in placenta.
CC   -!- PTM: Autophosphorylates upon activation by EFNA5. Phosphorylation on
CC       Tyr-602 mediates interaction with NCK1. Dephosphorylated by PTPN1.
CC       {ECO:0000269|PubMed:11870224, ECO:0000269|PubMed:18547520,
CC       ECO:0000269|PubMed:21135139}.
CC   -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease
CC       characterized by malignant lesions arising from the inner wall of the
CC       large intestine (the colon) and the rectum. Genetic alterations are
CC       often associated with progression from premalignant lesion (adenoma) to
CC       invasive adenocarcinoma. Risk factors for cancer of the colon and
CC       rectum include colon polyps, long-standing ulcerative colitis, and
CC       genetic family history. {ECO:0000269|PubMed:12738854}. Note=The gene
CC       represented in this entry may be involved in disease pathogenesis.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Ephrin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/EPHA3ID40463ch3p11.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M83941; AAA58633.1; -; mRNA.
DR   EMBL; AF213459; AAG43576.1; -; mRNA.
DR   EMBL; AF213460; AAG43577.1; -; mRNA.
DR   CCDS; CCDS2922.1; -. [P29320-1]
DR   CCDS; CCDS46875.1; -. [P29320-2]
DR   PIR; A38224; A38224.
DR   RefSeq; NP_005224.2; NM_005233.5. [P29320-1]
DR   RefSeq; NP_872585.1; NM_182644.2. [P29320-2]
DR   PDB; 2GSF; X-ray; 1.77 A; A=577-947.
DR   PDB; 2QO2; X-ray; 1.60 A; A=577-947.
DR   PDB; 2QO7; X-ray; 1.60 A; A=577-947.
DR   PDB; 2QO9; X-ray; 1.55 A; A=577-947.
DR   PDB; 2QOB; X-ray; 1.65 A; A=609-947.
DR   PDB; 2QOC; X-ray; 1.25 A; A=609-947.
DR   PDB; 2QOD; X-ray; 1.15 A; A=577-947.
DR   PDB; 2QOF; X-ray; 1.20 A; A=577-947.
DR   PDB; 2QOI; X-ray; 1.25 A; A=577-947.
DR   PDB; 2QOK; X-ray; 1.20 A; A=577-947.
DR   PDB; 2QOL; X-ray; 1.07 A; A=577-947.
DR   PDB; 2QON; X-ray; 1.79 A; A=577-947.
DR   PDB; 2QOO; X-ray; 1.25 A; A=577-947.
DR   PDB; 2QOQ; X-ray; 1.60 A; A=577-947.
DR   PDB; 3DZQ; X-ray; 1.75 A; A=609-947.
DR   PDB; 3FXX; X-ray; 1.70 A; A=577-947.
DR   PDB; 3FY2; X-ray; 1.80 A; A=577-947.
DR   PDB; 4G2F; X-ray; 1.70 A; A=609-947.
DR   PDB; 4GK2; X-ray; 2.20 A; A=609-947.
DR   PDB; 4GK3; X-ray; 1.90 A; A=609-947.
DR   PDB; 4GK4; X-ray; 2.10 A; A=609-947.
DR   PDB; 4L0P; X-ray; 2.26 A; A=29-201.
DR   PDB; 4P4C; X-ray; 1.60 A; A=609-947.
DR   PDB; 4P5Q; X-ray; 1.35 A; A=606-947.
DR   PDB; 4P5Z; X-ray; 2.00 A; A=606-947.
DR   PDB; 4TWN; X-ray; 1.71 A; A=609-947.
DR   PDB; 4TWO; X-ray; 2.05 A; A=609-947.
DR   PDB; 6IN0; X-ray; 1.50 A; A=612-904.
DR   PDBsum; 2GSF; -.
DR   PDBsum; 2QO2; -.
DR   PDBsum; 2QO7; -.
DR   PDBsum; 2QO9; -.
DR   PDBsum; 2QOB; -.
DR   PDBsum; 2QOC; -.
DR   PDBsum; 2QOD; -.
DR   PDBsum; 2QOF; -.
DR   PDBsum; 2QOI; -.
DR   PDBsum; 2QOK; -.
DR   PDBsum; 2QOL; -.
DR   PDBsum; 2QON; -.
DR   PDBsum; 2QOO; -.
DR   PDBsum; 2QOQ; -.
DR   PDBsum; 3DZQ; -.
DR   PDBsum; 3FXX; -.
DR   PDBsum; 3FY2; -.
DR   PDBsum; 4G2F; -.
DR   PDBsum; 4GK2; -.
DR   PDBsum; 4GK3; -.
DR   PDBsum; 4GK4; -.
DR   PDBsum; 4L0P; -.
DR   PDBsum; 4P4C; -.
DR   PDBsum; 4P5Q; -.
DR   PDBsum; 4P5Z; -.
DR   PDBsum; 4TWN; -.
DR   PDBsum; 4TWO; -.
DR   PDBsum; 6IN0; -.
DR   AlphaFoldDB; P29320; -.
DR   SMR; P29320; -.
DR   BioGRID; 108356; 52.
DR   DIP; DIP-40307N; -.
DR   IntAct; P29320; 76.
DR   MINT; P29320; -.
DR   STRING; 9606.ENSP00000337451; -.
DR   BindingDB; P29320; -.
DR   ChEMBL; CHEMBL4954; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; P29320; -.
DR   GuidetoPHARMACOLOGY; 1823; -.
DR   GlyGen; P29320; 5 sites.
DR   iPTMnet; P29320; -.
DR   MetOSite; P29320; -.
DR   PhosphoSitePlus; P29320; -.
DR   BioMuta; EPHA3; -.
DR   DMDM; 116241351; -.
DR   CPTAC; CPTAC-1774; -.
DR   jPOST; P29320; -.
DR   MassIVE; P29320; -.
DR   MaxQB; P29320; -.
DR   PaxDb; P29320; -.
DR   PeptideAtlas; P29320; -.
DR   PRIDE; P29320; -.
DR   ProteomicsDB; 54536; -. [P29320-1]
DR   ProteomicsDB; 54537; -. [P29320-2]
DR   ABCD; P29320; 1 sequenced antibody.
DR   Antibodypedia; 4182; 529 antibodies from 36 providers.
DR   DNASU; 2042; -.
DR   Ensembl; ENST00000336596.7; ENSP00000337451.2; ENSG00000044524.11. [P29320-1]
DR   Ensembl; ENST00000452448.6; ENSP00000399926.2; ENSG00000044524.11. [P29320-2]
DR   GeneID; 2042; -.
DR   KEGG; hsa:2042; -.
DR   MANE-Select; ENST00000336596.7; ENSP00000337451.2; NM_005233.6; NP_005224.2.
DR   UCSC; uc003dqx.2; human. [P29320-1]
DR   CTD; 2042; -.
DR   DisGeNET; 2042; -.
DR   GeneCards; EPHA3; -.
DR   HGNC; HGNC:3387; EPHA3.
DR   HPA; ENSG00000044524; Tissue enhanced (prostate).
DR   MIM; 114500; phenotype.
DR   MIM; 179611; gene.
DR   neXtProt; NX_P29320; -.
DR   OpenTargets; ENSG00000044524; -.
DR   PharmGKB; PA27819; -.
DR   VEuPathDB; HostDB:ENSG00000044524; -.
DR   eggNOG; KOG0196; Eukaryota.
DR   GeneTree; ENSGT00940000157088; -.
DR   HOGENOM; CLU_000288_141_3_1; -.
DR   InParanoid; P29320; -.
DR   OMA; NCKCEKN; -.
DR   PhylomeDB; P29320; -.
DR   TreeFam; TF315608; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   PathwayCommons; P29320; -.
DR   Reactome; R-HSA-2682334; EPH-Ephrin signaling.
DR   Reactome; R-HSA-3928663; EPHA-mediated growth cone collapse.
DR   Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells.
DR   SignaLink; P29320; -.
DR   SIGNOR; P29320; -.
DR   BioGRID-ORCS; 2042; 9 hits in 1108 CRISPR screens.
DR   ChiTaRS; EPHA3; human.
DR   EvolutionaryTrace; P29320; -.
DR   GeneWiki; EPH_receptor_A3; -.
DR   GenomeRNAi; 2042; -.
DR   Pharos; P29320; Tchem.
DR   PRO; PR:P29320; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; P29320; protein.
DR   Bgee; ENSG00000044524; Expressed in ganglionic eminence and 158 other tissues.
DR   ExpressionAtlas; P29320; baseline and differential.
DR   Genevisible; P29320; HS.
DR   GO; GO:0015629; C:actin cytoskeleton; IDA:HPA.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005769; C:early endosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043005; C:neuron projection; IBA:GO_Central.
DR   GO; GO:0031965; C:nuclear membrane; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0043235; C:receptor complex; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005003; F:ephrin receptor activity; IDA:ARUK-UCL.
DR   GO; GO:0005004; F:GPI-linked ephrin receptor activity; IDA:UniProtKB.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0005005; F:transmembrane-ephrin receptor activity; IBA:GO_Central.
DR   GO; GO:0007411; P:axon guidance; IBA:GO_Central.
DR   GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW.
DR   GO; GO:0016477; P:cell migration; ISS:UniProtKB.
DR   GO; GO:0071300; P:cellular response to retinoic acid; IMP:BHF-UCL.
DR   GO; GO:0048013; P:ephrin receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0097156; P:fasciculation of motor neuron axon; ISS:UniProtKB.
DR   GO; GO:0097155; P:fasciculation of sensory neuron axon; ISS:UniProtKB.
DR   GO; GO:0045806; P:negative regulation of endocytosis; IDA:UniProtKB.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0033674; P:positive regulation of kinase activity; IBA:GO_Central.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IMP:BHF-UCL.
DR   GO; GO:1903078; P:positive regulation of protein localization to plasma membrane; IDA:UniProtKB.
DR   GO; GO:0032956; P:regulation of actin cytoskeleton organization; IDA:UniProtKB.
DR   GO; GO:0010717; P:regulation of epithelial to mesenchymal transition; ISS:UniProtKB.
DR   GO; GO:0051893; P:regulation of focal adhesion assembly; IDA:UniProtKB.
DR   GO; GO:0043087; P:regulation of GTPase activity; IDA:UniProtKB.
DR   GO; GO:0070507; P:regulation of microtubule cytoskeleton organization; IDA:UniProtKB.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   CDD; cd10481; EphR_LBD_A3; 1.
DR   CDD; cd00063; FN3; 2.
DR   Gene3D; 1.10.150.50; -; 1.
DR   Gene3D; 2.60.40.10; -; 2.
DR   InterPro; IPR027936; Eph_TM.
DR   InterPro; IPR034266; EphA3_rcpt_lig-bd.
DR   InterPro; IPR001090; Ephrin_rcpt_lig-bd_dom.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR036116; FN3_sf.
DR   InterPro; IPR008979; Galactose-bd-like_sf.
DR   InterPro; IPR009030; Growth_fac_rcpt_cys_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001660; SAM.
DR   InterPro; IPR013761; SAM/pointed_sf.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR011641; Tyr-kin_ephrin_A/B_rcpt-like.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016257; Tyr_kinase_ephrin_rcpt.
DR   InterPro; IPR001426; Tyr_kinase_rcpt_V_CS.
DR   Pfam; PF14575; EphA2_TM; 1.
DR   Pfam; PF01404; Ephrin_lbd; 1.
DR   Pfam; PF07699; Ephrin_rec_like; 1.
DR   Pfam; PF00041; fn3; 2.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   Pfam; PF07647; SAM_2; 1.
DR   PIRSF; PIRSF000666; TyrPK_ephrin_receptor; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00615; EPH_lbd; 1.
DR   SMART; SM00060; FN3; 2.
DR   SMART; SM00454; SAM; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF47769; SSF47769; 1.
DR   SUPFAM; SSF49265; SSF49265; 1.
DR   SUPFAM; SSF49785; SSF49785; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 1.
DR   PROSITE; PS01186; EGF_2; 1.
DR   PROSITE; PS51550; EPH_LBD; 1.
DR   PROSITE; PS50853; FN3; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00790; RECEPTOR_TYR_KIN_V_1; 1.
DR   PROSITE; PS00791; RECEPTOR_TYR_KIN_V_2; 1.
DR   PROSITE; PS50105; SAM_DOMAIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell adhesion;
KW   Cell membrane; Direct protein sequencing; Glycoprotein; Kinase; Membrane;
KW   Nucleotide-binding; Phosphoprotein; Receptor; Reference proteome; Repeat;
KW   Secreted; Signal; Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase.
FT   SIGNAL          1..20
FT                   /evidence="ECO:0000269|PubMed:1737782"
FT   CHAIN           21..983
FT                   /note="Ephrin type-A receptor 3"
FT                   /id="PRO_0000016802"
FT   TOPO_DOM        21..541
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        542..565
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        566..983
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          29..207
FT                   /note="Eph LBD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00883"
FT   DOMAIN          325..435
FT                   /note="Fibronectin type-III 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          436..531
FT                   /note="Fibronectin type-III 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          621..882
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          911..975
FT                   /note="SAM"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00184"
FT   MOTIF           981..983
FT                   /note="PDZ-binding"
FT                   /evidence="ECO:0000255"
FT   ACT_SITE        746
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         628..633
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   BINDING         653
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   BINDING         700..706
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   BINDING         750..751
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   MOD_RES         596
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:11870224,
FT                   ECO:0000269|PubMed:18547520"
FT   MOD_RES         602
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:11870224,
FT                   ECO:0000269|PubMed:18547520"
FT   MOD_RES         701
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:18547520"
FT   MOD_RES         779
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:11870224"
FT   MOD_RES         937
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P29319"
FT   CARBOHYD        232
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        337
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        391
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        404
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        493
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   VAR_SEQ         532..539
FT                   /note="SFSISGES -> CMYYFNAV (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10987298"
FT                   /id="VSP_002995"
FT   VAR_SEQ         540..983
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10987298"
FT                   /id="VSP_002996"
FT   VARIANT         37
FT                   /note="T -> K (in a colorectal cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036086"
FT   VARIANT         85
FT                   /note="N -> S (in a colorectal cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036087"
FT   VARIANT         207
FT                   /note="K -> N (in a pancreatic ductal adenocarcinoma
FT                   sample; somatic mutation; dbSNP:rs200567888)"
FT                   /evidence="ECO:0000269|PubMed:20838624"
FT                   /id="VAR_068853"
FT   VARIANT         229
FT                   /note="S -> Y (in a lung large cell carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042126"
FT   VARIANT         449
FT                   /note="S -> F (in a lung neuroendocrine carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042127"
FT   VARIANT         518
FT                   /note="G -> L (in a lung squamous cell carcinoma sample;
FT                   somatic mutation; requires 2 nucleotide substitutions)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042128"
FT   VARIANT         564
FT                   /note="I -> V (in dbSNP:rs55712516)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042129"
FT   VARIANT         568
FT                   /note="C -> S (in dbSNP:rs56077781)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042130"
FT   VARIANT         590
FT                   /note="L -> P (in dbSNP:rs56081642)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042131"
FT   VARIANT         621
FT                   /note="I -> L (in a colorectal cancer sample; somatic
FT                   mutation; dbSNP:rs1414714315)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036088"
FT   VARIANT         660
FT                   /note="T -> K (in a lung carcinoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16941478"
FT                   /id="VAR_065831"
FT   VARIANT         766
FT                   /note="G -> E (in a lung adenocarcinoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042132"
FT   VARIANT         777
FT                   /note="A -> G (in dbSNP:rs34437982)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042133"
FT   VARIANT         806
FT                   /note="D -> N (in a colorectal cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036089"
FT   VARIANT         914
FT                   /note="R -> H (in dbSNP:rs17801309)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_027919"
FT   VARIANT         924
FT                   /note="W -> R (in dbSNP:rs35124509)"
FT                   /evidence="ECO:0000269|PubMed:1311845,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042134"
FT   VARIANT         933
FT                   /note="T -> M (in a lung carcinoma sample; somatic
FT                   mutation; dbSNP:rs372594677)"
FT                   /evidence="ECO:0000269|PubMed:16941478"
FT                   /id="VAR_065832"
FT   MUTAGEN         133
FT                   /note="V->E: Loss of EFNA5-binding ability and function."
FT                   /evidence="ECO:0000269|PubMed:14660665"
FT   MUTAGEN         152
FT                   /note="F->L: Loss of EFNA5-binding ability and function."
FT                   /evidence="ECO:0000269|PubMed:14660665"
FT   MUTAGEN         596
FT                   /note="Y->F: 10-fold suppression of kinase activity; when
FT                   associated with F-602. Full kinase activity; when
FT                   associated with F-602 and F-742. Full kinase activity; when
FT                   associated with F-602 and A-768."
FT                   /evidence="ECO:0000269|PubMed:18547520"
FT   MUTAGEN         602
FT                   /note="Y->F: 10-fold suppression of kinase activity; when
FT                   associated with F-596. Full kinase activity; when
FT                   associated with F-596 and F-742. Full kinase activity; when
FT                   associated with F-596 and A-768."
FT                   /evidence="ECO:0000269|PubMed:18547520"
FT   MUTAGEN         742
FT                   /note="Y->F: Full kinase activity; when associated with
FT                   F-596 and F-602."
FT                   /evidence="ECO:0000269|PubMed:18547520"
FT   MUTAGEN         768
FT                   /note="S->A: Full kinase activity; when associated with
FT                   F-596 and F-602."
FT                   /evidence="ECO:0000269|PubMed:18547520"
FT   CONFLICT        911
FT                   /note="T -> S (in Ref. 1; AAA58633)"
FT                   /evidence="ECO:0000305"
FT   STRAND          29..34
FT                   /evidence="ECO:0007829|PDB:4L0P"
FT   TURN            38..41
FT                   /evidence="ECO:0007829|PDB:4L0P"
FT   STRAND          45..48
FT                   /evidence="ECO:0007829|PDB:4L0P"
FT   STRAND          51..58
FT                   /evidence="ECO:0007829|PDB:4L0P"
FT   STRAND          64..71
FT                   /evidence="ECO:0007829|PDB:4L0P"
FT   STRAND          75..77
FT                   /evidence="ECO:0007829|PDB:4L0P"
FT   STRAND          80..83
FT                   /evidence="ECO:0007829|PDB:4L0P"
FT   STRAND          96..104
FT                   /evidence="ECO:0007829|PDB:4L0P"
FT   HELIX           106..108
FT                   /evidence="ECO:0007829|PDB:4L0P"
FT   STRAND          117..128
FT                   /evidence="ECO:0007829|PDB:4L0P"
FT   STRAND          130..132
FT                   /evidence="ECO:0007829|PDB:4L0P"
FT   HELIX           137..139
FT                   /evidence="ECO:0007829|PDB:4L0P"
FT   STRAND          141..147
FT                   /evidence="ECO:0007829|PDB:4L0P"
FT   HELIX           154..159
FT                   /evidence="ECO:0007829|PDB:4L0P"
FT   STRAND          165..170
FT                   /evidence="ECO:0007829|PDB:4L0P"
FT   STRAND          176..200
FT                   /evidence="ECO:0007829|PDB:4L0P"
FT   TURN            610..612
FT                   /evidence="ECO:0007829|PDB:2QOL"
FT   HELIX           618..620
FT                   /evidence="ECO:0007829|PDB:2QOL"
FT   STRAND          621..629
FT                   /evidence="ECO:0007829|PDB:2QOL"
FT   STRAND          631..641
FT                   /evidence="ECO:0007829|PDB:2QOL"
FT   STRAND          647..654
FT                   /evidence="ECO:0007829|PDB:2QOL"
FT   HELIX           661..674
FT                   /evidence="ECO:0007829|PDB:2QOL"
FT   STRAND          685..689
FT                   /evidence="ECO:0007829|PDB:2QOL"
FT   STRAND          691..694
FT                   /evidence="ECO:0007829|PDB:2QOL"
FT   STRAND          696..700
FT                   /evidence="ECO:0007829|PDB:2QOL"
FT   HELIX           707..712
FT                   /evidence="ECO:0007829|PDB:2QOL"
FT   TURN            713..716
FT                   /evidence="ECO:0007829|PDB:2QOL"
FT   HELIX           720..739
FT                   /evidence="ECO:0007829|PDB:2QOL"
FT   HELIX           749..751
FT                   /evidence="ECO:0007829|PDB:2QOL"
FT   STRAND          752..754
FT                   /evidence="ECO:0007829|PDB:2QOL"
FT   STRAND          760..762
FT                   /evidence="ECO:0007829|PDB:2QOL"
FT   HELIX           765..768
FT                   /evidence="ECO:0007829|PDB:4TWN"
FT   HELIX           788..790
FT                   /evidence="ECO:0007829|PDB:2QOD"
FT   HELIX           793..798
FT                   /evidence="ECO:0007829|PDB:2QOL"
FT   HELIX           803..818
FT                   /evidence="ECO:0007829|PDB:2QOL"
FT   TURN            819..821
FT                   /evidence="ECO:0007829|PDB:2QO9"
FT   TURN            824..827
FT                   /evidence="ECO:0007829|PDB:2QOL"
FT   HELIX           830..838
FT                   /evidence="ECO:0007829|PDB:2QOL"
FT   HELIX           851..860
FT                   /evidence="ECO:0007829|PDB:2QOL"
FT   HELIX           865..867
FT                   /evidence="ECO:0007829|PDB:2QOL"
FT   HELIX           871..883
FT                   /evidence="ECO:0007829|PDB:2QOL"
FT   HELIX           885..889
FT                   /evidence="ECO:0007829|PDB:2QOL"
FT   STRAND          890..892
FT                   /evidence="ECO:0007829|PDB:4G2F"
FT   STRAND          898..903
FT                   /evidence="ECO:0007829|PDB:2QOC"
SQ   SEQUENCE   983 AA;  110131 MW;  BE04DBF958245424 CRC64;
     MDCQLSILLL LSCSVLDSFG ELIPQPSNEV NLLDSKTIQG ELGWISYPSH GWEEISGVDE
     HYTPIRTYQV CNVMDHSQNN WLRTNWVPRN SAQKIYVELK FTLRDCNSIP LVLGTCKETF
     NLYYMESDDD HGVKFREHQF TKIDTIAADE SFTQMDLGDR ILKLNTEIRE VGPVNKKGFY
     LAFQDVGACV ALVSVRVYFK KCPFTVKNLA MFPDTVPMDS QSLVEVRGSC VNNSKEEDPP
     RMYCSTEGEW LVPIGKCSCN AGYEERGFMC QACRPGFYKA LDGNMKCAKC PPHSSTQEDG
     SMNCRCENNY FRADKDPPSM ACTRPPSSPR NVISNINETS VILDWSWPLD TGGRKDVTFN
     IICKKCGWNI KQCEPCSPNV RFLPRQFGLT NTTVTVTDLL AHTNYTFEID AVNGVSELSS
     PPRQFAAVSI TTNQAAPSPV LTIKKDRTSR NSISLSWQEP EHPNGIILDY EVKYYEKQEQ
     ETSYTILRAR GTNVTISSLK PDTIYVFQIR ARTAAGYGTN SRKFEFETSP DSFSISGESS
     QVVMIAISAA VAIILLTVVI YVLIGRFCGY KSKHGADEKR LHFGNGHLKL PGLRTYVDPH
     TYEDPTQAVH EFAKELDATN ISIDKVVGAG EFGEVCSGRL KLPSKKEISV AIKTLKVGYT
     EKQRRDFLGE ASIMGQFDHP NIIRLEGVVT KSKPVMIVTE YMENGSLDSF LRKHDAQFTV
     IQLVGMLRGI ASGMKYLSDM GYVHRDLAAR NILINSNLVC KVSDFGLSRV LEDDPEAAYT
     TRGGKIPIRW TSPEAIAYRK FTSASDVWSY GIVLWEVMSY GERPYWEMSN QDVIKAVDEG
     YRLPPPMDCP AALYQLMLDC WQKDRNNRPK FEQIVSILDK LIRNPGSLKI ITSAAARPSN
     LLLDQSNVDI TTFRTTGDWL NGVWTAHCKE IFTGVEYSSC DTIAKISTDD MKKVGVTVVG
     PQKKIISSIK ALETQSKNGP VPV
//
